Jun 08,2016

Insulet to Present Omnipod® Clinical Studies on Type 1 and Type 2 Diabetes During the American Diabetes Association's 76th Scientific Sessions

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced new clinical data for the Company's Omnipod System will be presented at the American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans, La., June 10-14, 2016.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 09,2016

ASCENSIA DIABETES CARE RENEWS INTERNATIONAL ALLIANCE WITH MEDTRONIC

Today Ascensia Diabetes Care announced that it has renewed its global alliance with Medtronic plc to develop and market innovative diabetes management solutions for patients worldwide. As part of the agreement, Ascensia Diabetes Care will continue to exclusively co-develop and supply CONTOUR™ NEXT LINK and CONTOUR™ PLUS LINK blood glucose meters that are wirelessly compatible to communicate with Medtronic's integrated insulin pump and continuous glucose monitoring (CGM) systems.

COLLABORATION PARTNERSHIP

#product & service

#bgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 10,2016

Insulet Partners with Joslin Diabetes Center to Implement a Unique Training Certification for Insulet's Clinical Team

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that almost 100 members of Insulet's North American clinical team have completed a customized certification program designed and led by the Joslin Diabetes Center for Insulet. The Advanced Diabetes Educator in Pump Therapy (ADEPT™) certification provides Insulet's clinical team with customized, advanced training to deliver enhanced support for individuals who are managing their diabetes using continuous subcutaneous insulin infusion therapy. The Company's partnership with Joslin will enable Insulet's clinical team to provide unparalleled training and support for healthcare practitioners and their Omnipod patients.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 11,2016

New Data Demonstrate Benefits of Insulet's Omnipod® System for People with Type 1 and Type 2 Diabetes

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), today announced two online publications of new data in the Journal of Diabetes Science and Technology that provide evidence supporting the benefits of the Omnipod System in patients with type 1 and type 2 diabetes. The data show the Omnipod System is effective in controlling blood glucose levels in patients after switching from multiple daily injections (MDI) or from traditional tubed insulin pumps.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 11,2016

USABILITY AND ACCURACY DATA FOR ASCENSIA DIABETES CARE BLOOD GLUCOSE MONITORING SYSTEMS PRESENTED IN POSTERS AT THE AMERICAN DIABETES ASSOCIATION'S 76TH SCIENTIFIC SESSIONS

At the American Diabetes Association's 76th Scientific Sessions this week, data are being presented from three studies that evaluated the accuracy and usability of blood glucose monitoring systems from Ascensia Diabetes Care. This is the first presentation of data for the CONTOUR® NEXT ONE blood glucose monitoring system evaluating ease-of-use in the hands of subjects with diabetes. The study by Bailey et al. (Poster 81-LB), assessed the usability of the CONTOUR® NEXT ONE blood glucose meter with the CONTOUR® Diabetes App in 43 individuals with type 1 and type 2 diabetes. An investigator-initiated study, presented by Dr. Guido Freckmann (Poster 898-P), evaluated the accuracy of the CONTOUR® NEXT LINK 2.4 meter.

CLINICAL STUDY

#bgm

View Analyst & Ambassador Comments
Go to original news
Jul 19,2016

Medtronic gets CE Mark for smartphone-connected CGM

Medtronic has received a CE Mark for its Guardian Connect mobile continuous glucose monitor (CGM) and app. The company will begin selling the system in select countries in Europe, Asia, and Latin America in Q2 2017 and expects to receive FDA clearance to launch the device in the US around that same time.

REGULATORY CE MARK

#cgm

#mobile app

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jul 22,2016

FDA panel advises agency to greenlight Dexcom G5 CGM as replacement to fingerstick treatment decisions

An FDA advisory panel has voted in favor of recommending a change to the intended use of Dexcom’s G5 Continuous Glucose Monitor (CGM). The G5 had already been FDA-approved, but with limitations as an adjunctive device, meaning it could only be used for tracking and trending interstitial fluid gluocose concentrations rather than as a full replacement for a traditional fingerstick blood glucose meter (BGM).

View Analyst & Ambassador Comments
Go to original news
Jul 25,2016

DreaMed raises $3.3M for its diabetes management clinical decision support software

Israel-based DreaMed Diabetes announced this week that it has raised $3.3 million from Norma Investments, Russian businessman Roman Abramovich and one other unnamed angel.

FUNDING VENTURE ROUND
View Analyst & Ambassador Comments
Go to original news
Jul 26,2016

AMA becomes advisor to Omada Health in its rollout of a diabetes prevention program at Intermountain

San Francisco-based Omada Health, an online and mobile behavioral medicine company, announced today a partnership with the American Medical Association and a new customer, Utah-based Intermountain Healthcare system, which will offer Omada’s flagship diabetes prevention program (DPP), Prevent, to its patients. All three organizations will collaborate to integrate Omada’s diabetes prevention program into Intermountain’s system, with the AMA acting as an advisor to Omada to help it better understand how to make Prevent better integrate into providers' workflows.

COLLABORATION PARTNERSHIP

#insurance

#coaching

View Analyst & Ambassador Comments
Go to original news
Jul 28,2016

Lilly-backed smartphone-enabled insulin pen gets FDA nod

Companion Medical, a stealthy San Diego-based company that received funding last year from Eli Lilly and Company, has received FDA 510(k) clearance for its Bluetooth-connected smart insulin pen and associated mobile app, called InPen.

REGULATORY FDA

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES